Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Nov 07 | 2022Lilly Connected Pen US Launch in 2022; Lannett Partners with Ypsomed; Eversense to Integrate with Apple; Viatris Q3 ’22 Earnings Update; November CHMP AgendaPurchase Blast
$599
Posted in: Other, SGLT2i Nov 04 | 2022EMPA-KIDNEY Demonstrates 28% RRR @ ASN 2022; Sernova to Expand Ph1/2 Patient Cohort; Creative Medical Cell Therapy IND Granted FDA Clearance; Senseonics/Ascensia Collaborate with NPG to Expand Eversense CGM Access; Amgen Q3 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Insulin Delivery, Other Nov 03 | 2022Insulet, Provention Bio, Madrigal, and Regeneron Q3 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal, Other Nov 03 | 2022Novo Q3 ’22 London EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Nov 02 | 2022Tandem and Lannett Q3 ’22 Earnings Updates; Indigo Expands into US; OrsoBio Acquires T2DM and NASH AssetsPurchase Blast$599
Posted in: Basal Insulin, GLP-1RA, Other Nov 02 | 2022Novo Nordisk Q3 ’22 Earnings Update; FY Guidance RaisedPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Nov 01 | 2022Pfizer, Esperion, and Intercept Q3 ’22 Earnings Updates; First Patient Dosed in Biomea’s Ph1/2 BMF-219 T2DM TrialPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Insulin Delivery, Other Nov 01 | 2022Lilly Q3 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Oct 28 | 2022Vertex and Sanofi Q3 ’22 Earnings Updates; Sciwind Reports Positive Interim Results from Ph2b Ecnoglutide Obesity TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 27 | 2022Dexcom Q3 ’22 Earnings Update; Kerendia Receives New Recommendations from ADA and KDIGOPurchase Blast
$599
Posted in: Other Oct 27 | 2022Teladoc, Alnylam, and Amarin Q3 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery, Other Oct 26 | 2022Biocorp and Novo Sign New Connected Care Agreement; Daprodustat Adcom: 13-3 in Favor of Dapro in DD; 5-11 Against Dapro in NDDPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Oct 25 | 2022Novartis and Adocia Q3 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Other Oct 21 | 2022Biocon Receives Second Bs-aspart CRL; EMA Approves Malaysian FacilityPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Oct 20 | 2022Abbott Q3 ’22 Earnings Update; EMA Expects Ozempic Supply Shortage Into 2023Purchase Blast
$599
Posted in: Insulin Delivery, Other, SGLT2i Oct 18 | 2022Medtronic Launches 770G Personalized Insights Program; GSK Initiates Ph2b NASH Trial; J&J Q3 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other Oct 17 | 2022Insulet to Replace Omnipod DASH PDMs; Pfizer Initiates New Ph2 QD Oral GLP-1RA vs. Rybelsus Trial; Novartis to Lay Off 400 Employees in DublinPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 12 | 2022Sarissa Capital Challenges Amarin’s Management; Nemaura Receives Provisional Purchase Order from TPMENAPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 11 | 2022Roche Diabetes Partners with New Mark Cuban CompanyPurchase Blast
$599
Posted in: Bolus Insulin, Other Oct 11 | 2022Lilly Partners with Nimbus Therapeutics for Metabolic Drug Discovery; Arecor Reports Positive Topline Results from Second Ph1 uRAI TrialPurchase Blast